Gubra A/S (CPH:GUBRA)
Denmark
· Delayed Price · Currency is DKK | Market Cap | 6.29B |
| Revenue (ttm) | 2.64B |
| Net Income (ttm) | 1.69B |
| Shares Out | 16.33M |
| EPS (ttm) | 102.70 |
| PE Ratio | 3.75 |
| Forward PE | 160.42 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 66,612 |
| Average Volume | 35,579 |
| Open | 375.00 |
| Previous Close | 391.00 |
| Day's Range | 371.20 - 389.60 |
| 52-Week Range | 318.40 - 730.00 |
| Beta | 0.34 |
| RSI | 46.65 |
| Earnings Date | Feb 27, 2026 |
About Gubra
Gubra A/S, a biotech company, focuses on the pre-clinical contract research and peptide-based drug discovery within metabolic and fibrotic diseases in Europe, North America, and internationally. The company operates through three segments: Pre-Clinical Contract Research (CRO), Discovery & Partnerships, and Gubra Green. It offers pre-clinical contract research and development services within metabolic and fibrotic diseases for the pharmaceutical and biotechnology industry, as well as provides services in vivo pharmacology, biomarker assays, bioi... [Read more]
Financial Performance
Financial StatementsNews
Full Year 2025 Gubra A/S Earnings Call Transcript
Full Year 2025 Gubra A/S Earnings Call Transcript
Gubra’s Innovation in Peptide-Based Drug Discovery
Founded in 2008, Gubra is a highly specialized preclinical CRO and biotech company focused on peptide-based drug discovery within metabolic and fibrotic diseases. In this interview, CEO Henrik Blou re...
Healthy Returns: AbbVie is the newest potential weight loss drug market player
AbbVie will pay up to $2.2 billion to develop Danish drugmaker Gubra's obesity drug. AI takes center stage at HIMSS conference gets underway in Vegas.
AbbVie Steps Into The Ring In The Obesity Drug Wars
AbbVie's strategic move into the obesity market through a partnership with Gubra A/S shows potential but won't impact revenue. Click to read why ABBV is a Hold.
AbbVie Becomes Another Big Pharma To Enter Obesity Treatment Race
On Monday, AbbVie Inc (NYSE: ABBV) and Gubra A/S announced a license agreement to develop GUB014295, a long-acting amylin analog for obesity. GUB014295 is currently in a Phase 1 clinical trial . “Our...
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2194283489-73fa751504b949af8f17e8f2726d50e5.jpg)
AbbVie Joins Obesity Treatment Market With Up to $2.2B Licensing Deal
Drugmaker AbbVie has agreed to license a weight-loss drug currently in development from Gubra for up to about $2.2 billion, marking its entry into the obesity treatment market.
AbbVie (ABBV) Enters Weight Loss Market with $2.2 Billion Gubra Deal
AbbVie (ABBV) Enters Weight Loss Market with $2.2 Billion Gubra Deal
AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion.
AbbVie inked a licensing deal Monday worth up to $2.23 billion for an amylin-targeting obesity treatment from Denmark-based Gubra A/S.
AbbVie forays into obesity market with up to $2.2B Gubra license deal
Danish Biotech Gubra Says Obesity Drug Positive in Early Trial
Danish biotech Gubra A/S said its experimental obesity drug showed weight loss and mild side effects in a small study, clearing a crucial early hurdle.